Advanced

The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders

Hultqvist, Malin LU ; Kutty Selva, Nandakumar LU ; Bjorklund, U and Holmdahl, Rikard LU (2009) In Annals of the Rheumatic Diseases 68(1). p.130-135
Abstract
Objectives: Autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) affect a relatively large portion of the population, leading to severe disability if left untreated. Even though pharmaceutics targeting the immune system have revolutionised the therapy of these diseases, there is still a need for novel, more effective therapeutic substances. One such substance is the new chemical entity 9-chloro-2,3 dimethyl-6-(N, N-dimthylamino-2-oxoethyl)-6H-indolo [2,3-b] quionoxaline, Rabeximod, currently being investigated for efficiency in treatment of human RA. In this study we aimed to evaluate Rabeximod as a treatment for autoimmune diseases, using animal models. Methods: In the present investigation we have evaluated... (More)
Objectives: Autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) affect a relatively large portion of the population, leading to severe disability if left untreated. Even though pharmaceutics targeting the immune system have revolutionised the therapy of these diseases, there is still a need for novel, more effective therapeutic substances. One such substance is the new chemical entity 9-chloro-2,3 dimethyl-6-(N, N-dimthylamino-2-oxoethyl)-6H-indolo [2,3-b] quionoxaline, Rabeximod, currently being investigated for efficiency in treatment of human RA. In this study we aimed to evaluate Rabeximod as a treatment for autoimmune diseases, using animal models. Methods: In the present investigation we have evaluated Rabeximod as a treatment for autoimmune diseases using mouse models of RA and MS, ie, collagen-induced arthritis, collagen antibody induced arthritis and experimental autoimmune encephalomyelitis. Results: Rabeximod efficiently prevented arthritis and encephalomyelitis in mice. In addition, this effect correlated to the timepoint when cells migrate into the joints. Conclusions: We conclude that Rabeximod reduces disease severity in animal models of autoimmunity and should be considered as a new therapeutic substance for MS and RA. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of the Rheumatic Diseases
volume
68
issue
1
pages
130 - 135
publisher
British Medical Association
external identifiers
  • wos:000261755800023
  • scopus:58349110928
ISSN
1468-2060
DOI
10.1136/ard.2007.085241
language
English
LU publication?
yes
id
84916284-213b-45fc-ae84-a9e6811782f2 (old id 1313839)
date added to LUP
2009-03-06 15:02:37
date last changed
2017-01-01 06:28:59
@article{84916284-213b-45fc-ae84-a9e6811782f2,
  abstract     = {Objectives: Autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) affect a relatively large portion of the population, leading to severe disability if left untreated. Even though pharmaceutics targeting the immune system have revolutionised the therapy of these diseases, there is still a need for novel, more effective therapeutic substances. One such substance is the new chemical entity 9-chloro-2,3 dimethyl-6-(N, N-dimthylamino-2-oxoethyl)-6H-indolo [2,3-b] quionoxaline, Rabeximod, currently being investigated for efficiency in treatment of human RA. In this study we aimed to evaluate Rabeximod as a treatment for autoimmune diseases, using animal models. Methods: In the present investigation we have evaluated Rabeximod as a treatment for autoimmune diseases using mouse models of RA and MS, ie, collagen-induced arthritis, collagen antibody induced arthritis and experimental autoimmune encephalomyelitis. Results: Rabeximod efficiently prevented arthritis and encephalomyelitis in mice. In addition, this effect correlated to the timepoint when cells migrate into the joints. Conclusions: We conclude that Rabeximod reduces disease severity in animal models of autoimmunity and should be considered as a new therapeutic substance for MS and RA.},
  author       = {Hultqvist, Malin and Kutty Selva, Nandakumar and Bjorklund, U and Holmdahl, Rikard},
  issn         = {1468-2060},
  language     = {eng},
  number       = {1},
  pages        = {130--135},
  publisher    = {British Medical Association},
  series       = {Annals of the Rheumatic Diseases},
  title        = {The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders},
  url          = {http://dx.doi.org/10.1136/ard.2007.085241},
  volume       = {68},
  year         = {2009},
}